RNPEP — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL530834	0.53	4/20
SCHEMBL995721	0.42	4/20
SCHEMBL387310	0.41	4/20
Hydrochloric Acid (SCHEMBL56160)	0.40	4/20
Hydrochloric Acid (SCHEMBL56161)	0.40	4/20
SCHEMBL770554	0.40	4/20
SCHEMBL770555	0.40	4/20
SCHEMBL996374	0.38	4/20
SCHEMBL891923	0.36	4/20
SCHEMBL768465	0.61	3/20
SCHEMBL933573	0.61	3/20
SCHEMBL26550	0.59	3/20
SCHEMBL931181	0.59	3/20
SCHEMBL414209	0.58	3/20
SCHEMBL107723	0.52	3/20
SCHEMBL11129	0.47	3/20
SCHEMBL637786	0.46	3/20
SCHEMBL637801	0.46	3/20
SCHEMBL620369	0.44	3/20
SCHEMBL620370	0.44	3/20

Clinical trials — most relevant to RNPEP by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effect of Renin-angiotensin-system Blockade on Urinary Free Light Chains in Patients With Type 2 Diabetes Mellitus	PHASE4	COMPLETED
Efficacy of Candesartan on Symptomatic Heart Failure in Treating Diabetic and Hypertensive Patients.	PHASE3	COMPLETED
Injection of Recombinant Human Tissue-type Plasminogen Activator Derivative for Acute Pulmonary Embolism(rPA)	PHASE2	UNKNOWN
Tranexamic Acid (TXA) and Corona Virus 2019 (COVID19) in Inpatients	PHASE2	WITHDRAWN
A PhaseⅡ of Injection for Recombinant Human Tissue Plasminogen Kinase Derivative in Treatment of Acute Ischemic Stroke.	PHASE2	UNKNOWN
Roflumilast in Non-CF Bronchiectasis Study (2019)	PHASE2	COMPLETED
A Trial of Carboxypeptidase-G2 (CPDG2) and Thymidine for the Management of Patients With Methotrexate Toxicity and Renal Dysfunction	PHASE1	COMPLETED
A Cut-off Value Study of N-terminal Brain Natriuretic Peptide （Chemiluminescence Method）	nan	COMPLETED
An Analysis of Urinary Proteases as Biomarkers for Hepatocellular Carcinoma-101423	nan	COMPLETED
Ovarian Reserve and Matrix Metalloproteinases	nan	COMPLETED
Mepolizumab Effectiveness in Patients With Chronic Rhinosinusitis, Nasal Polyps and Comorbid Severe Eosinophilic Asthma	nan	ACTIVE_NOT_RECRUITING
Study of Tissue, Blood, and Urine Samples From Patients With Advanced Prostate Cancer	nan	UNKNOWN
Protein Digestion and Amino Acid Absorption in the Aging Gastrointestinal Tract	nan	COMPLETED
Influence of Statins in Artery Aneurysms	nan	UNKNOWN
Respiratory Cathepsins, Proteases Inhibitors and Glycosaminoglycans (GAG) in Mucopolysaccharidosis	nan	COMPLETED
Apelin12 in Acne Vulgaris	nan	UNKNOWN
Diagnostic and Prognostic Role of Troponin and Brain Natriuretic Peptide in Pediatric Patients With Cardiomyopathy in Correlation to Echocardiography Findings	nan	UNKNOWN
Surfactant Derived Protocol in Heart Failure	nan	COMPLETED
Markers in Acute Pancreatitis-1	nan	COMPLETED
Acute Pancreatitis Targets (APT) Study	nan	COMPLETED
Open-Label Expanded Access Treatment With Pegunigalsidase Alfa for Fabry Disease Patients	nan	APPROVED_FOR_MARKETING
The Efficacy and Safety of Switch Between Agalsidase Beta to Agalsidase Alfa for Enzyme Replacement in Patients With Anderson-Fabry Disease	nan	COMPLETED
Influence of Genetic Polymorphisms on Ventricular Structure and Function in Patients With Single Ventricle Anatomy	nan	COMPLETED
The Association Between Asparaginase Enzyme Activity Levels and Toxicities in Childhood Acute Lymphoblastic Leukaemia in NOPHOALL 2008	nan	COMPLETED
Correlation Between Serum Markers of Unstable Plaque and Virtual Histology of Unstable Plaque Visualized by IVUS	nan	COMPLETED
Clearance of Vasoactive Metabolites With Blood Purification	nan	RECRUITING
Catalytic Antibodies to Predict Uninvasively Late Transplant Failure	nan	COMPLETED
Disorders of the Acute Phase Response Following Trauma and Invasive Surgery	nan	ENROLLING_BY_INVITATION
Impact of the Genetic Polymorphism on COVID-19 in Egypt	nan	UNKNOWN
MMP Polymorphisms and Acute Coronary Syndromes	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a RNPEP binder may also engage these)

Protein	Name	Similarity
Q8VCT3	—	1.000	Q8VCT3 →
O09175	—	1.000	O09175 →
G5E872	—	0.990	G5E872 →
Q9HAU8	—	0.985	Q9HAU8 →
A6H611	—	0.963	A6H611 →
Q69ZF3	—	0.961	Q69ZF3 →
Q99797	—	0.961	Q99797 →
RIOX2	Ribosomal oxygenase 2	0.959	landscape →
Q01992	—	0.959	Q01992 →
P47823	—	0.959	P47823 →
Q1JPJ8	—	0.959	Q1JPJ8 →
Q5NVK5	—	0.959	Q5NVK5 →
Q5RF14	—	0.959	Q5RF14 →
EIF2B5	Translation initiation factor eIF2B subunit epsilon	0.958	landscape →
Q5EA80	—	0.958	Q5EA80 →
Q5M868	—	0.958	Q5M868 →
A5A779	—	0.958	A5A779 →
P55345	—	0.958	P55345 →
Q9R144	—	0.958	Q9R144 →
Q8BVG4	—	0.957	Q8BVG4 →
F1NZI4	—	0.956	F1NZI4 →
P47788	—	0.956	P47788 →
LPCAT1	Lysophosphatidylcholine acyltransferase 1	0.956	landscape →
Q9JHK4	—	0.956	Q9JHK4 →
Q9MYY0	—	0.956	Q9MYY0 →
Q9BSK4	—	0.955	Q9BSK4 →
DPP9	Dipeptidyl peptidase 9	0.955	landscape →
A5PK19	—	0.955	A5PK19 →
THOP1	Thimet oligopeptidase	0.955	landscape →
Q9BRR6	—	0.955	Q9BRR6 →